These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 23203637

  • 1. SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer.
    de Ronde JJ, Lips EH, Mulder L, Vincent AD, Wesseling J, Nieuwland M, Kerkhoven R, Vrancken Peeters MJ, Sonke GS, Rodenhuis S, Wessels LF.
    Breast Cancer Res Treat; 2013 Jan; 137(1):213-23. PubMed ID: 23203637
    [Abstract] [Full Text] [Related]

  • 2. Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765).
    Noske A, Loibl S, Darb-Esfahani S, Roller M, Kronenwett R, Müller BM, Steffen J, von Toerne C, Wirtz R, Baumann I, Hoffmann G, Heinrich G, Grasshoff ST, Ulmer HU, Denkert C, von Minckwitz G.
    Breast Cancer Res Treat; 2011 Feb; 126(1):109-17. PubMed ID: 21190079
    [Abstract] [Full Text] [Related]

  • 3. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Nikolényi A, Sükösd F, Kaizer L, Csörgo E, Vörös A, Uhercsák G, Ormándi K, Lázár G, Thurzó L, Brodowicz T, Kahán Z.
    Oncology; 2011 Feb; 80(3-4):269-77. PubMed ID: 21734419
    [Abstract] [Full Text] [Related]

  • 4. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A, Karn T, Gätje R, Kourtis K, Minckwitz G, Loibl S, Munnes M, Ruckhäberle E, Holtrich U, Kaufmann M, Ahr A.
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [Abstract] [Full Text] [Related]

  • 5. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.
    Lips EH, Mulder L, de Ronde JJ, Mandjes IA, Vincent A, Vrancken Peeters MT, Nederlof PM, Wesseling J, Rodenhuis S.
    Breast Cancer Res Treat; 2012 Feb; 131(3):827-36. PubMed ID: 21472434
    [Abstract] [Full Text] [Related]

  • 6. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study.
    Huober J, von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM, Belau A, Khandan F, Hauschild M, Thomssen C, Högel B, Darb-Esfahani S, Mehta K, Loibl S.
    Breast Cancer Res Treat; 2010 Nov; 124(1):133-40. PubMed ID: 20697801
    [Abstract] [Full Text] [Related]

  • 7. TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy.
    Wang J, Xu B, Yuan P, Zhang P, Li Q, Ma F, Fan Y.
    Breast Cancer Res Treat; 2012 Sep; 135(2):531-7. PubMed ID: 22864769
    [Abstract] [Full Text] [Related]

  • 8. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
    von Minckwitz G, Darb-Esfahani S, Loibl S, Huober J, Tesch H, Solbach C, Holms F, Eidtmann H, Dietrich K, Just M, Clemens MR, Hanusch C, Schrader I, Henschen S, Hoffmann G, Tiemann K, Diebold K, Untch M, Denkert C.
    Breast Cancer Res Treat; 2012 Apr; 132(3):863-70. PubMed ID: 21667238
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial.
    Riethdorf S, Müller V, Zhang L, Rau T, Loibl S, Komor M, Roller M, Huober J, Fehm T, Schrader I, Hilfrich J, Holms F, Tesch H, Eidtmann H, Untch M, von Minckwitz G, Pantel K.
    Clin Cancer Res; 2010 May 01; 16(9):2634-45. PubMed ID: 20406831
    [Abstract] [Full Text] [Related]

  • 15. Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients.
    Kariya S, Ogawa Y, Nishioka A, Moriki T, Ohnishi T, Ito S, Murata Y, Yoshida S.
    Radiat Med; 2005 May 01; 23(3):189-94. PubMed ID: 15940066
    [Abstract] [Full Text] [Related]

  • 16. HER2 and responsiveness of breast cancer to adjuvant chemotherapy.
    Pritchard KI, Shepherd LE, O'Malley FP, Andrulis IL, Tu D, Bramwell VH, Levine MN, National Cancer Institute of Canada Clinical Trials Group.
    N Engl J Med; 2006 May 18; 354(20):2103-11. PubMed ID: 16707747
    [Abstract] [Full Text] [Related]

  • 17. [Immunohistochemical phenotype of breast carcinomas predicts the effectiveness of primary systemic therapy].
    Kulka J, Tokés AM, Tóth AI, Szász AM, Farkas A, Borka K, Járay B, Székely E, Istók R, Lotz G, Madaras L, Korompay A, Harsányi L, László Z, Rusz Z, Molnár BA, Molnár IA, Kenessey I, Szentmártoni G, Székely B, Dank M.
    Magy Onkol; 2009 Dec 18; 53(4):335-43. PubMed ID: 20071305
    [Abstract] [Full Text] [Related]

  • 18. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.
    Bartlett JM, Munro A, Cameron DA, Thomas J, Prescott R, Twelves CJ.
    J Clin Oncol; 2008 Nov 01; 26(31):5027-35. PubMed ID: 18768436
    [Abstract] [Full Text] [Related]

  • 19. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
    Dressler LG, Berry DA, Broadwater G, Cowan D, Cox K, Griffin S, Miller A, Tse J, Novotny D, Persons DL, Barcos M, Henderson IC, Liu ET, Thor A, Budman D, Muss H, Norton L, Hayes DF.
    J Clin Oncol; 2005 Jul 01; 23(19):4287-97. PubMed ID: 15994142
    [Abstract] [Full Text] [Related]

  • 20. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
    Orlando L, Del Curto B, Gandini S, Ghisini R, Pietri E, Torrisi R, Balduzzi A, Cardillo A, Dellapasqua S, Veronesi P, Viale G, Goldhirsch A, Colleoni M.
    Breast; 2008 Oct 01; 17(5):506-11. PubMed ID: 18456496
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.